Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9949461 | 0.90 | FGFR3 (0.82) | FGFR3KDR | |
| SCHEMBL3323065 | 0.90 | KDR (0.83) | FGFR3KDR | |
| SCHEMBL9949931 | 0.89 | FGFR3 (1.00) | FGFR3KDR | |
| SCHEMBL9949442 | 0.88 | FGFR3 (0.81) | FGFR3KDR | |
| SCHEMBL9951278 | 0.88 | FGFR3 (0.79) | FGFR3KDR | |
| SCHEMBL9949873 | 0.85 | FGFR3 (1.00) | FGFR3KDR | |
| SCHEMBL9949423 | 0.85 | FGFR3 (0.71) | FGFR3KDR | |
| SCHEMBL13336725 | 0.81 | KDR (0.70) | FGFR3KDR | |
| Hydrochloric Acid SCHEMBL3322807 | 0.81 | KDR (0.69) | FGFR3KDR | |
| SCHEMBL3324176 | 0.81 | KDR (0.69) | FGFR3KDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10813930-B2 | Substituted imidazopyridazines and benzimidazoles as inhibitors of FGFR3 | INCYTE CORPORATION (US) | 2020-10-27 | — | — | US | disclosed |
| US-10813930-B2 | Substituted imidazopyridazines and benzimidazoles as inhibitors of FGFR3 | INCYTE CORPORATION (US) | 2020-10-27 | — | — | US | disclosed |
| US-20190240220-A1 | SUBSTITUTED IMIDAZOPYRIDAZINES AND BENZIMIDAZOLES AS INHIBITORS OF FGFR3 | INCYTE CORPORATION | 2019-08-08 | — | — | US | disclosed |
| US-20190240220-A1 | SUBSTITUTED IMIDAZOPYRIDAZINES AND BENZIMIDAZOLES AS INHIBITORS OF FGFR3 | INCYTE CORPORATION | 2019-08-08 | — | — | US | disclosed |
| US-20170165263-A1 | SUBSTITUTED IMIDAZOPYRIDAZINES AND BENZIMIDAZOLES AS INHIBITORS OF FGFR3 | INCYTE CORPORATION | 2017-06-15 | — | — | US | disclosed |
| US-20170165263-A1 | SUBSTITUTED IMIDAZOPYRIDAZINES AND BENZIMIDAZOLES AS INHIBITORS OF FGFR3 | INCYTE CORPORATION | 2017-06-15 | — | — | US | disclosed |
| US-9533954-B2 | Substituted imidazopyridazines and benzimidazoles as inhibitors of FGFR3 | INCYTE CORPORATION (US) | 2017-01-03 | — | — | US | disclosed |
| US-20140243308-A1 | SUBSTITUTED IMIDAZOPYRIDAZINES AND BENZIMIDAZOLES AS INHIBITORS OF FGFR3 | INCYTE CORPORATION (US) | 2014-08-28 | — | — | US | disclosed |
| US-20140243308-A1 | SUBSTITUTED IMIDAZOPYRIDAZINES AND BENZIMIDAZOLES AS INHIBITORS OF FGFR3 | INCYTE CORPORATION (US) | 2014-08-28 | — | — | US | disclosed |
| US-8754114-B2 | Substituted imidazopyridazines and benzimidazoles as inhibitors of FGFR3 | INCYTE CORPORATION (US) | 2014-06-17 | — | — | US | disclosed |
| US-8754114-B2 | Substituted imidazopyridazines and benzimidazoles as inhibitors of FGFR3 | INCYTE CORPORATION (US) | 2014-06-17 | — | — | US | disclosed |
| US-20120165305-A1 | SUBSTITUTED IMIDAZOPYRIDAZINES AND BENZIMIDAZOLES AS INHIBITORS OF FGFR3 | INCYTE CORPORATION | 2012-06-28 | — | — | US | disclosed |
| US-20120165305-A1 | SUBSTITUTED IMIDAZOPYRIDAZINES AND BENZIMIDAZOLES AS INHIBITORS OF FGFR3 | INCYTE CORPORATION | 2012-06-28 | — | — | US | disclosed |
| WO-2012088266-A2 | SUBSTITUTED IMIDAZOPYRIDAZINES AND BENZIMIDAZOLES AS INHIBITORS OF FGFR3 | INCYTE CORPORATION (US) | 2012-06-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190240220-A1 | SUBSTITUTED IMIDAZOPYRIDAZINES AND BENZIMIDAZOLES AS INHIBITORS OF FGFR3 | FGFR3, FGFR4, FGFR2 | FGFR3 1/4885KDR 133/4885 |
| US-20120165305-A1 | SUBSTITUTED IMIDAZOPYRIDAZINES AND BENZIMIDAZOLES AS INHIBITORS OF FGFR3 | FGFR3, FGFR4, FGFR2 | FGFR3 1/4885KDR 133/4885 |
| US-10813930-B2 | Substituted imidazopyridazines and benzimidazoles as inhibitors of FGFR3 | FGFR3, FGFR4, FGFR2 | FGFR3 1/4885KDR 133/4885 |
| US-20170165263-A1 | SUBSTITUTED IMIDAZOPYRIDAZINES AND BENZIMIDAZOLES AS INHIBITORS OF FGFR3 | FGFR3, FGFR4, FGFR2 | FGFR3 1/4885KDR 133/4885 |
| US-20140243308-A1 | SUBSTITUTED IMIDAZOPYRIDAZINES AND BENZIMIDAZOLES AS INHIBITORS OF FGFR3 | FGFR3, FGFR4, FGFR2 | FGFR3 1/4885KDR 133/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.